248 related articles for article (PubMed ID: 21540615)
1. Feasibility of delayed hyperthermic intraperitoneal chemotherapy in case of unforeseen complications.
Mohr Z; Hirche C; Liebeskind U; Rau B; Hünerbein M
Eur Surg Res; 2011; 47(1):19-25. PubMed ID: 21540615
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies.
Kusamura S; Baratti D; Deraco M
Ann Surg; 2012 Feb; 255(2):348-56. PubMed ID: 22202584
[TBL] [Abstract][Full Text] [Related]
3. Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kusamura S; Baratti D; Antonucci A; Younan R; Laterza B; Oliva GD; Gavazzi C; Deraco M
Ann Surg Oncol; 2007 Dec; 14(12):3443-52. PubMed ID: 17909918
[TBL] [Abstract][Full Text] [Related]
4. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
Piso P; Slowik P; Popp F; Dahlke MH; Glockzin G; Schlitt HJ
Ann Surg Oncol; 2009 Aug; 16(8):2188-94. PubMed ID: 19408049
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
Kusamura S; Baratti D; Younan R; Laterza B; Oliva GD; Costanzo P; Favaro M; Gavazzi C; Grosso F; Deraco M
Ann Surg Oncol; 2007 Sep; 14(9):2550-8. PubMed ID: 17558537
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
Baratti D; Pennacchioli E; Kusamura S; Fiore M; Balestra MR; Colombo C; Mingrone E; Gronchi A; Deraco M
Ann Surg Oncol; 2010 Dec; 17(12):3220-8. PubMed ID: 20585874
[TBL] [Abstract][Full Text] [Related]
8. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
10. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
[TBL] [Abstract][Full Text] [Related]
11. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
12. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
[TBL] [Abstract][Full Text] [Related]
13. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.
Golse N; Bakrin N; Passot G; Mohamed F; Vaudoyer D; Gilly FN; Glehen O; Cotte E
J Surg Oncol; 2012 Aug; 106(2):197-203. PubMed ID: 22331814
[TBL] [Abstract][Full Text] [Related]
14. Aggressive locoregional management of recurrent peritoneal sarcomatosis.
Baumgartner JM; Ahrendt SA; Pingpank JF; Holtzman MP; Ramalingam L; Jones HL; Zureikat AH; Zeh HJ; Bartlett DL; Choudry HA
J Surg Oncol; 2013 Mar; 107(4):329-34. PubMed ID: 23386388
[TBL] [Abstract][Full Text] [Related]
15. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
[TBL] [Abstract][Full Text] [Related]
17. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
Witkamp AJ; de Bree E; Kaag MM; van Slooten GW; van Coevorden F; Zoetmulder FA
Br J Surg; 2001 Mar; 88(3):458-63. PubMed ID: 11260116
[TBL] [Abstract][Full Text] [Related]
18. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
Chua TC; Quinn LE; Zhao J; Morris DL
J Surg Oncol; 2013 Aug; 108(2):81-8. PubMed ID: 23737041
[TBL] [Abstract][Full Text] [Related]
19. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
Bhagwandin SB; Naffouje S; Salti G
J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
Lim SJ; Cormier JN; Feig BW; Mansfield PF; Benjamin RS; Griffin JR; Chase JL; Pisters PW; Pollock RE; Hunt KK
Ann Surg Oncol; 2007 Aug; 14(8):2309-18. PubMed ID: 17541691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]